The recent approval of CD19 T cell therapy in B cell acute lymphoblastic leukemia (bALL) and diffuse large B cell lymphoma (DLBCL) provides a strong clinical validation of CAR-T therapy and provides an impetus to develop T cell therapy beyond CD19+ B malignancies. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.